Menu Search
Equities

Ironwood Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
I76:DUS

Ironwood Pharmaceuticals Inc

Actions
  • Price (EUR)3.66
  • Today's Change-0.16 / -4.19%
  • Shares traded300.00
  • 1 Year change+114.04%
  • Beta0.1990
Data delayed at least 15 minutes, as of Feb 11 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

  • Revenue in USD (TTM)338.99m
  • Net income in USD28.55m
  • Incorporated1998
  • Employees253.00
  • Location
    Ironwood Pharmaceuticals Inc100 Summer Street, Suite 2300BOSTON 02110United StatesUSA
  • Phone+1 (617) 621-7722
  • Fax+1 (617) 494-0480
  • Websitehttps://www.ironwoodpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.